GZR33 vs Insulin glargine (Basaglar)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor (basal) · full Type 2 Diabetes pipeline

GZR33

Developed by Gan & Lee Pharmaceuticals

Phase 3 in Type 2 Diabetespeptide
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Insulin glargine (Basaglar)

Marketed by Eli Lilly and partners

Approved in Type 2 Diabetespeptide
Partial signal

NCT01421459 · Phase 3 · completed

The study was randomized, triple-blind, and active-controlled, with 759 participants, but its primary endpoint was HbA1c, a laboratory surrogate rather than a hard clinical outcome. The prespecified non-inferiority comparison was met: the 95% confidence interval for the treatment difference remained below the +0.4% margin.

Reported efficacy

Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) (Baseline, Week 24): LY2963016 -1.27 Percentage of HbA1c (Standard Error 0.043) vs Lantus® -1.23 Percentage of HbA1c (Standard Error 0.062) (met)

Result source: NCT03338010

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointGZR33Insulin glargine (Basaglar)
HbA1c, change—Trial running · NCT07527078-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459
Body weight, change (kg)—Trial running · NCT075270781.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459
HbA1c below 7%—Trial running · NCT0752707843.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010
Fasting plasma glucose, change—Trial running · NCT07527078—Not reported
3-point MACE (% with event)—Trial running · NCT07527078—Not reported

HbA1c, change

GZR33
—Trial running · NCT07527078
Insulin glargine (Basaglar)
-1.3% vs -1.3%vs Lantuswk 24 · n 369NCT01421459
9 other results
  • -1.3% vs -1.2% wk 24 · n 226 · Phase 3 · primary NCT02302716
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · primary NCT03338010
  • -1.3% vs -1.4% wk 24 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.2% wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • -1.3% vs -1.4% wk 20 · n 369 · Phase 3 · secondary NCT01421459
  • -1.3% vs -1.3% wk 16 · n 369 · Phase 3 · secondary NCT01421459
  • -1.1% vs -1.1% wk 12 · n 369 · Phase 3 · secondary NCT01421459
  • -0.9% vs -0.9% wk 8 · n 369 · Phase 3 · secondary NCT01421459
  • -0.5% vs -0.5% wk 4 · n 369 · Phase 3 · secondary NCT01421459

Body weight, change (kg)

GZR33
—Trial running · NCT07527078
Insulin glargine (Basaglar)
1.9 vs 2.2vs Lantuswk 24 · n 370NCT01421459
7 other results
  • 2.3 vs 1.7 wk 24 · n 229 · Phase 3 · secondary NCT02302716
  • 1.1 vs 1.2 wk 24 · n 334 · Phase 3 · secondary NCT03338010
  • 1.7 vs 2.2 wk 20 · n 370 · Phase 3 · secondary NCT01421459
  • 1.6 vs 1.9 wk 16 · n 370 · Phase 3 · secondary NCT01421459
  • 1.3 vs 1.4 wk 12 · n 370 · Phase 3 · secondary NCT01421459
  • 1.0 vs 1.2 wk 8 · n 370 · Phase 3 · secondary NCT01421459
  • 0.3 vs 0.5 wk 4 · n 370 · Phase 3 · secondary NCT01421459

HbA1c below 7%

GZR33
—Trial running · NCT07527078
Insulin glargine (Basaglar)
43.7% vs 44.9%vs Lantus®wk 24 · n 334NCT03338010

Fasting plasma glucose, change

GZR33
—Trial running · NCT07527078
Insulin glargine (Basaglar)
—Not reported

3-point MACE (% with event)

GZR33
—Trial running · NCT07527078
Insulin glargine (Basaglar)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

GZR33: no structured comparison results are available for Type 2 Diabetes.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. GZR33: 0 of 4 rows · Insulin glargine (Basaglar): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricInsulin glargine (Basaglar)
Dropout rate
11.9%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
7.6%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
6.4%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
28.3%
NCT04153981 · Phase 4 · registry result, not featured evidence
Discontinued due to AEs
1.6%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
0.4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
0.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
—
NCT04153981 · Phase 4 · registry result, not featured evidence
Serious AEs
4%a
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
4%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
7.8%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence
Most frequent reported AEs
a
nasopharyngitis 5.6%
upper respiratory tract infection 5.1%
abnormal weight gain 2.7%
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 3 more results
nasopharyngitis 7.2%
upper respiratory tract infection 4%
weight increased 3.2%
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
upper respiratory tract infection 20.3%
hypertension 5.6%
injection site pain 4.2%
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
anaemia 1.9%
cough 0.4%
hyperglycaemia 0.4%
NCT04153981 · Phase 4 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 1 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Insulin glargine (Basaglar)

HbA1c -1.286% (n=369) vs -1.338% (n=375) Lantus @ 24wk
absolute change · percentage points
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 9 more results
-0.452% (n=369) vs -0.481% (n=375) Lantus @ 4wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-0.871% (n=369) vs -0.866% (n=375) Lantus @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.134% (n=369) vs -1.143% (n=375) Lantus @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.265% (n=369) vs -1.321% (n=375) Lantus @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.294% (n=369) vs -1.379% (n=375) Lantus @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.336% (n=369) vs -1.438% (n=375) Lantus @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.25% (n=226) vs -1.22% (n=223) LANTUS® @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
-1.27% (n=334) vs -1.23% (n=158) Lantus® @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
-1.27% (n=334) vs -1.23% (n=158) Lantus® @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight 0.292 vs 0.526 Lantus kg @ 4wk
absolute change · kg
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
show 7 more results
0.999 vs 1.152 Lantus kg @ 8wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.271 vs 1.44 Lantus kg @ 12wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.55 vs 1.918 Lantus kg @ 16wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.734 vs 2.234 Lantus kg @ 20wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.914 vs 2.175 Lantus kg @ 24wk
NCT01421459 · Phase 3 · combination · Type 2 Diabetes · phase 3
2.3 vs 1.7 LANTUS® kg @ 24wk
NCT02302716 · Phase 3 · combination · Type 2 Diabetes · phase 3
1.1 vs 1.2 Lantus® kg @ 24wk
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than 7% 43.7% (n=334) vs 44.9% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
HbA1c Less Than or Equal to 6.5 23.4% (n=334) vs 16.5% (n=158) Lantus® @ 24wk
responder rate · % of participants
NCT03338010 · Phase 3 · monotherapy · Type 2 Diabetes · phase 3
Weight -0.5 kg @ 24wk
absolute change · kg
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
HbA1c -0.641% (n=259) @ 12wk
absolute change · percentage points
No placebo or comparator arm
NCT04153981 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.86% (n=259) @ 24wk
NCT04153981 · Phase 4 · registry result, not featured evidence
SMBG 7-point Change mg/dL -38.7 mg @ 24wk
absolute change · mg
No placebo or comparator arm
Blood glucose concentration before breakfast
NCT04153981 · Phase 4 · registry result, not featured evidence

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GZR33's landscape · Insulin glargine (Basaglar)'s landscape